3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
4
Sarcoma
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Thoracic
1
Endocrine
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
86
Lung Neoplasms
32
Small Cell Lung Carcinoma
18
Melanoma
17
Mesothelioma
13
Neoplasms
11
Colorectal Neoplasms
9
Carcinoma, Renal Cell
9
Squamous Cell Carcinoma of Head and Neck
7
Neoplasm Metastasis
7
Mesothelioma, Malignant
7
Carcinoma, Transitional Cell
7
Ovarian Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Liver Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Hepatocellular
5
Uterine Cervical Neoplasms
4
Stomach Neoplasms
4
Kidney Neoplasms
4
Brain Neoplasms
4
Carcinoma, Merkel Cell
3
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Interventions
pembrolizumab
4
spartalizumab
2
toripalimab
1
tislelizumab
1
atezolizumab
1
Quality of Life
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Ipilimumab
1
Immunotherapy
1
Immunoglobulin G
1
Drug Therapy
1
Disulfides
1
Biological Therapy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Nasopharyngeal Carcinoma
×
Ipilimumab
×
Thoracic
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled